This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dingli, D. Articles by Gertz, M. A. Search for Related Content PubMed PubMed Citation Articles by Dingli, D. Articles by Gertz, M. A. Social Bookmarking                            What's this?

Relationship Between Depth of Response and Outcome in Multiple Myeloma

David Dingli, Jorge M. Pacheco, Grzegorz S. Nowakowski, Shaji K. Kumar, Angela Dispenzieri, Suzanne R. Hayman, Martha Q. Lacy, Dennis A. Gastineau, Morie A. Gertz

From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN; and the Centro de Fisica Teórica e Computacional and Departamento de Fisica da Universidade de Lisboa, Portugal

Address reprint requests to Morie A. Gertz, MD, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905; e-mail: gertz.morie{at}mayo.edu

Purpose High-dose therapy with autologous stem-cell transplantation (HDT-ASCT) is now almost standard therapy for many patients with multiple myeloma, partly because of higher complete response (CR) rates. Some studies suggest that tandem transplantation gives superior results. The aim of this study was to determine whether the depth of the response to HDT-ASCT leads to an improvement in time to progression (TTP) and overall survival (OS). We hypothesized that patients with CR before HDT-ASCT (BCR) will have their disease burden reduced further and experience a longer TTP and perhaps OS.

Patients and Methods All patients who achieved BCR or CR after HDT-ASCT (ACR) were identified. The characteristics and long-term outcome of these patients were evaluated.

Results We identified 14 patients with BCR and 103 patients with ACR who were treated in similar fashion. The patients have been followed for more than 6 years, and the median for OS has not been reached (60-month survival, 55% for BCR and 63% for ACR; P = .83). The median TTP was 43 months for BCR and 34 months for ACR (P = .39).

Conclusion The depth of the response in myeloma does not necessarily lead to an improvement in TTP and OS. Tumor dynamics considerations show that the yield from sequential cycles of chemotherapy decreases. Patients who achieve CR with the first transplant can be safely observed without jeopardizing OS.

Supported by the Mayo Foundation (D.D.) and FCT Portugal (J.M.P.).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J.-L. Harousseau, M. Attal, and H. Avet-Loiseau The role of complete response in multiple myeloma Blood, October 8, 2009; 114(15): 3139 - 3146. [Abstract] [Full Text] [PDF]

				M. M. Giarin, L. Giaccone, R. Sorasio, C. Sfiligoi, B. Amoroso, F. Cavallo, A. Cipriani, A. Palumbo, and M. Boccadoro Serum Free Light Chain Ratio, Total {kappa}/{lambda} Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Clin. Chem., August 1, 2009; 55(8): 1510 - 1516. [Abstract] [Full Text] [PDF]

				B. Bruno, M. Rotta, F. Patriarca, D. Mattei, B. Allione, F. Carnevale-Schianca, R. Sorasio, A. Rambaldi, M. Casini, M. Parma, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo Blood, April 2, 2009; 113(14): 3375 - 3382. [Abstract] [Full Text] [PDF]

				J. J. Lahuerta, M. V. Mateos, J. Martinez-Lopez, L. Rosinol, A. Sureda, J. de la Rubia, J. Garcia-Larana, R. Martinez-Martinez, M. T. Hernandez-Garcia, D. Carrera, et al. Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival J. Clin. Oncol., December 10, 2008; 26(35): 5775 - 5782. [Abstract] [Full Text] [PDF]